Fibroblasts from phenotypically normal palmar fascia exhibit molecular profiles highly similar to fibroblasts from active disease in Dupuytren's Contracture

BMC Medical Genomics

Volumn 5, Issue , 2012, Pages

  Satish, Latha ^a   Laframboise, William A ^b   Johnson, Sandra ^c   Vi, Linda ^d   Njarlangattil, Anna ^d   Raykha, Christina ^d   Krill Burger, John Michael ^b   Gallo, Phillip H ^a   O'Gorman, David B ^d   Gan, Bing Siang ^d   Baratz, Mark E ^c   Ehrlich, Garth D ^c   Kathju, Sandeep ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

^d ST JOSEPH S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; MESSENGER RNA; MICRORNA; MICRORNA 106A; MICRORNA 122; MICRORNA 17; MICRORNA 202; MICRORNA 20B; MICRORNA 214; UNCLASSIFIED DRUG; RNA;

ANGIOPOIETIN LIKE 7 GENE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DUPUYTREN CONTRACTURE; FIBROBLAST; GENE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC DIFFERENCE; GENETIC PREDISPOSITION; HUMAN; HUMAN CELL; HUMAN TISSUE; INGENUITY PATHWAY ANALYSIS; INTERNAL CONSISTENCY; LAMININ ALPHA5 GENE; MICROARRAY ANALYSIS; MOLECULAR PATHOLOGY; PALMAR FASCIA; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE REAL TIME POLYMERASE CHAIN REACTION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT DISEASE; SHROOM2 MESSAGE GENE; TRANSCRIPTOMICS; VALIDATION PROCESS; CELL CULTURE; CLUSTER ANALYSIS; CYTOLOGY; DNA MICROARRAY; FASCIA; GENE EXPRESSION PROFILING; ISOLATION AND PURIFICATION; METABOLISM; PATHOLOGY;

CELLS, CULTURED; CLUSTER ANALYSIS; COLLAGEN TYPE I; DUPUYTREN CONTRACTURE; FASCIA; FIBROBLASTS; GENE EXPRESSION PROFILING; HUMANS; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; RNA;

EID: 84860537899     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-5-15     Document Type: Article

References (45)

1. Pathogenesis of Dupuytren's contracture a correlative clinical-pathological study. Chiu HF, McFarlane RM, J Hand Surg [Am] 1978 3 1 10 (Pubitemid 8283397)
2. Epidemiology of Dupuytren's disease. Ross DC, Hand Clinics 1999 15 53 62 10050242 (Pubitemid 29066104)
3. Mapping of an autosomal dominant gene for Dupuytren's contracture to chromosome 16q in a Swedish family. Hu FZ, Nystrom A, Ahmed A, Palmquist M, Dopico R, Mossberg I, Gladitz J, Rayner M, Post JC, Ehrlich GD, Preston RA, Clin Genet 2005 68 424 429 10.1111/j.1399-0004.2005.00504.x 16207209 (Pubitemid 41535966)
4. The heritability of Dupuytren's disease: familial aggregation and its clinical significance. Hindocha S, John S, Stanley JK, Watson SJ, Bayat A, J Hand Surg [Am] 2006 31 204 210 10.1016/j.jhsa.2005.09.018 (Pubitemid 43227269)
5. Dupuytren's disease risk factors. Geoghegan JM, Forbes J, Clark DI, Smith C, Hubbard R, J Hand Surg [Br] 2004 29 423 426 10.1016/j.jhsb.2004.06.006 (Pubitemid 39186084)
6. A prospective study linked both alcohol and tobacco to Dupuytren's disease. Godtfredsen NS, Lucht H, Prescott E, Sorensen TI, Gronbaek M, J Clin Epidemiol 2004 57 858 863 10.1016/j.jclinepi.2003.11.015 15485739 (Pubitemid 39370171)
7. Prevalence of Dupuytren's contracture and its correlation with degenerative changes of the hands and feet and with criteria of general health. Bergenudd H, Lindgarde F, Nilsson BE, J Hand Surg [Br] 1993 18 254 257 10.1016/0266-7681(93)90123-W (Pubitemid 23119146)
8. Dupuytren's contracture in manual workers. Bennett B, Br J Ind Med 1982 39 98 100 7066227 (Pubitemid 12132458)
9. Risks and prevention of Dupuytren's contracture. Frey M, Lancet 1997 350 1568 10.1016/S0140-6736(05)64010-X 9393334 (Pubitemid 28036598)
10. New insights in the development of Dupuytren's Contracture: A review. Kloen P, Br J Plast Surg 1999 52 629 635 10.1054/bjps.1999.3187 10658134
11. Is diabetes mellitus type 2 a risk factor for Dupuytren's contracture in the Mediterranean region? Akyol A, Kiylioglu N, Copcu E, Guney E, Aydeniz A, Plast Reconstr Surg 2006 117 2105 2106 10.1097/01.prs.0000214746.17066.2e 16652017 (Pubitemid 44324424)
12. The injection of nodules of Dupuytren's disease with triamcinolone acetonide. Ketchum LD, Donahue TK, J Hand Surg 2000 25A: 1157 1162
13. Effect of gamma-interferon on the clinical and biologic evolution of hypertrophic scars and Dupuytren's disease: an open pilot study. Pittet B, Rubbia-Brandt L, Desmoulière A, Sappino AP, Roggero P, Guerret S, Grimaud JA, Lacher R, Montandon D, Gabbiani G, Plast Reconstr Surg 1994 93 1224 1235 10.1097/00006534-199405000-00018 8171142 (Pubitemid 24273751)
14. Dupuytren's contracture treated with vitamin E. Richard H, Br Med J 1952 1 1320 1321
15. DMSO in the treatment of Dupuytren's contracture. A therapeutic experiment. Vuopala U, Kaipainen W, Acta Rheum Scand 1971 17 61 62 5552618
16. Ultrasonic therapy in Dupuytren's contracture. Stiles P, J Bone Joint Surg Br 1966 48 452 454 5913136
17. Nonoperative treatment of Dupuytren's disease. Hurst LC, Badalamente MA, Hand Clinics 1999 15 97 107 10050246 (Pubitemid 29066108)
18. Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren's contracture. Badalamente MA, Hurst LC, J Hand Surg [Am] 2007 32 767 774 10.1016/j.jhsa.2007.04.002 (Pubitemid 46991162)
19. Injectable collagenase clostridium for Dupuytren's contracture. Hurst LC, Badalamente MA, Hentz VR, Hotchkiss RN, Kaplan FT, Meals RA, Smith TM, Rodzvilla J, CORD I Study Group, N Engl J Med 2009 361 968 979 10.1056/NEJMoa0810866 19726771
20. Results following surgery for recurrent Dupuytren's disease. Roush TF, Stern PJ, J Hand Surg [Am] 2000 25 291 296 10.1053/jhsu.2000.jhsu25a0291 (Pubitemid 30165593)
21. A review of common practice in Dupuytren surgery. Au-Yong IT, Wildin CJ, Dias JJ, Page RE, Tech Hand Up Extrem Surg 2005 9 178 187 10.1097/01.bth. 0000186794.90431.a4 16340578 (Pubitemid 44510276)
22. Wound healing-associated proteins Hsp47 and fibronectin are elevated in Dupuytren's contracture. Howard JC, Varallo VM, Ross DC, Faber KJ, Roth JH, Seney S, Gan BS, J Surg Res 2004 117 232 238 10.1016/j.jss.2004.01.013 15047128 (Pubitemid 38393648)
23. Identification of differentially expressed genes in fibroblasts derived from patients with Dupuytrens Contracture. Satish L, LaFramboise WA, O'Gorman DB, Johnson S, Janto B, Gan BS, Baratz ME, Hu FZ, Post JC, Ehrlich GD, Kathju S, BMC Med Genomics 2008 1 10 10.1186/1755-8794-1-10 18433489
24. Type-1 collagen differentially alters beta-catenin accumulation in primary Dupuytren's disease cord and adjacent palmar fascia cells. Vi L, Njarlangattil A, Wu Y, Gan BS, O'Gorman DB, BMC Musculoskelet Disord 2009 10 72 10.1186/1471-2474-10-72 19545383
25. Significance analysis of microarrays applied to the ionizing radiation response. Tusher VG, Tibshirani R, Chu G, Proc Natl Acad Sci USA 2001 98 5116 5121 http://www-stat.Stanford.edu/∼tibs/SAM/ 10.1073/pnas.091062498 11309499 (Pubitemid 32397092)
26. Sneath PHA, Sokal RR, Numerical Taxonomy San Francisco: W.H. Free-man 1973
27. -catenin Signaling in Fibroproliferative Disease. Bowley E, O'Gorman DB, Gan BS, Journal of Surgical Research 2007 138 1 141 150 10.1016/j.jss.2006.07. 026 17109886 (Pubitemid 46227458)
28. Tissue stiffness, latent TGF-beta1 activation, and mechanical signal transduction: implications for the pathogenesis and treatment of fibrosis. Hinz B, Curr Rheumatol Rep 2009 11 120 126 10.1007/s11926-009-0017-1 19296884
29. Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. Wipff PJ, Rifkin DB, Meister JJ, Hinz B, J Cell Biol 2007 179 1311 1323 10.1083/jcb.200704042 18086923 (Pubitemid 350277747)
30. beta1-Integrin-collagen interaction suppresses FoxO3a by the corordination of Akt and PP2A. Nho RS, Kahm J, J Biol Chem 2010 285 14195 209 10.1074/jbc.M109.052845 20223831
31. Identification of Mesenchymal Stem Cells in Perinodular Fat and Skin in Dupuytren's Disease: A Potential Source of Myofibroblasts with Implications for Pathogenesis and Therapy. Iqbal SA, Manning C, Syed F, Kolluru V, Hayton M, Watson S, Bayat A, Stem Cells Dev 2012 21 4 609 622 10.1089/scd.2011.0140 21612554
32. Mutation and cancer: statistical study of retinoblastoma. Knudson AG Jr, Proc Natl Acad Sci USA 1971 68 820 823 10.1073/pnas.68.4.820 5279523
33. A new theory on cancer-inducing mechanism. Nordling CO, Br J Cancer 1953 7 68 72 10.1038/bjc.1953.8 13051507
34. Elevated transforming growth factor and mitogen-activated protein kinase pathways mediate fibrotic traits of Dupuytren's disease fibroblasts. Krause C, Kloen P, Ten Dijke P, Fibrogenesis Tissue Repair 2011 4 1 14 10.1186/1755-1536-4-14 21711521
35. An integrated proteomics approach for studying the molecular pathogenesis of Dupuytren's disease. Kraljevic Pavelic S, Sedic M, Hock K, Vucinic S, Jurisic D, Gehrig P, Scott M, Schlapbach R, Cacev T, Kapitanovic S, Pavelic K, J Pathol 2009 217 4 524 33 10.1002/path.2483 19089850
36. Comparative integromics on angiopoietin family members. Katoh Y, Katoh M, Int J Mol Med 2006 17 1145 1149 16685428
37. Angiopoietin-like 7 secretion is induced by glaucoma stimuli and its concentration is elevated in glaucomatous aqueous humor. Kuchtey J, Källberg ME, Gelatt KN, Rinkoski T, Komromy AM, Kuchtey RW, Invest Opthalmol Vis Sci 2008 49 3438 3448 10.1167/iovs.07-1347
38. Evidence for a role of ANGPTL7 in extracellular matrix formation of the human trabecular meshwork: implications for glaucoma. Comes N, Buie LK, Borrs T, Genes to Cells 2011 16 243 259 10.1111/j.1365-2443.2010.01483.x 21199193
39. Laminin isoforms in development and disease. Scheele S, Nystrom A, Durbeej M, et al. J Mol Med 2007 85 825 836 10.1007/s00109-007-0182-5 17426950 (Pubitemid 47077111)
40. Bridging structure with function: structural, regulatory, and developmental role of laminins. Tzu J, Marinkovich MP, Int J Biochem Cell Biol 2008 40 199 214 10.1016/j.biocel.2007.07.015 17855154 (Pubitemid 350137873)
41. Differential expression of fibronectin splice variants, oncofetal glycosylated fibronectin and laminin isoforms in nodular palmar fibromatosis. Kosmehl H, Berndt A, Katenkamp D, Mandel U, Bohle R, Gabler U, Celeda D, Pathol Res Pract 1995 191 1105 1113 10.1016/S0344-0338(11)80655-2 8822112 (Pubitemid 26031756)
42. Differential actin-dependent localization modulates the evolutionarily conserved activity of Shroom family proteins. Dietz ML, Bernaciak TM, Vendetti F, Kielec JM, Hildebrand JD, J Biol Chem 2006 281 20542 20554 10.1074/jbc.M512463200 16684770 (Pubitemid 44065826)
43. Shroom4 (Kiaa 1202) is an actin-associated protein implicated in cytokeletal organization. Yoder M, Hildebrand JD, Cell Motil Cytoskeleton 2007 64 49 63 10.1002/cm.20167 17009331 (Pubitemid 44927728)
44. Shroom family proteins regulate gamma-tubulin distribution and microtubule architecture during epithelial cell shape change. Lee C, Scherr HM, Wallingford JB, Development 2007 134 1431 1441 10.1242/dev.02828 17329357 (Pubitemid 46706048)
45. Unique microRNA profile in Dupuytren's contracture supports deregulation of -catenin pathway. Mosakhani N, Guled M, Lahti L, Borze I, Forsman M, Pääkkönen V, Ryhänen J, Knuutila S, Modern Pathology 2010 23 1544 1552 10.1038/modpathol.2010.146 20676061